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Foreword
This monograph is a publication of original research focused on biopharmaceutical sector Knowledge 
Management (KM) methodologies and capabilities. The authors, through their research, have developed 
models, tools and processes which can assist the sector gain greater clarity of the value and merits that KM 
can offer to organisations. 
Kane’s research was driven by a determination to close the gap from KM theory to practice.
Her research addresses a void of research in, and understanding of, the concept of KM in the biopharma 
sector, and proposes a foundational Pharma KM Blueprint (Kane 2018).  The Pharma KM Blueprint illustrates 
holistic integration of core KM principles, models and tools to deliver real benefits to the patients and the 
business. 
The Pharma KM Blueprint is comprised of several elements, including:
•  Recognising Knowledge as an Asset - Identifies the need to value and maintain knowledge assets in 
the same way as physical assets within an organisation
•  The Pharmaceutical Product Knowledge Lifecycle Model (PPKL) - Addresses the challenge of 
enabling knowledge flow in order to increase visibility, access to and use of the product and process 
knowledge assets across the product lifecycle 
• The House of Knowledge Excellence (HoKE) Framework – Demonstrates a framework developed 
to implement a systematic KM programme linked to strategic objectives of an organisation, 
incorporating KM practices, pillars, and enablers to support the effective management and flow of 
knowledge assets. 
•  A Knowledge Management Effectiveness Evaluation (KMEE) - A practical KM diagnostic tool 
that may be used to identify and evaluate areas of opportunity and to track progress on closing 
knowledge gaps. 
This research has already spawned additional research on the KM topic, including research by co-author 
Lipa further exploring the PPKL topic of tacit knowledge in technology transfer.  Lipa’s research is on-going, 
but an early output is a confirmation that knowledge transfer as part of technology transfer is often not 
effective.  Lipa goes on to propose a framework for enhancing knowledge transfer known as the Knowledge 
Transfer Enhancement (KTE) Framework.  Research is continuing on this topic and will be the subject of future 
publications.
It is hoped that these research outputs and corresponding dialogue within the biopharma industry will lead 
to meaningful improvements for the industry and for the patients who depend on it.  
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1. Chapter One  
 Monograph Background and Context
In 2005 The International Conference on Harmonisastion (CH) published a concept paper for ICH Q10 
Pharmaceutical Quality System (International Conference on Harmonisation, 2005a) , where the topic of 
knowledge management (KM) made a formal entrance to the global regulatory landscape for the first time, 
and was identified as one of the two enablers underpinning an effective Pharmaceutical Quality System (PQS), 
along with quality risk management (QRM), as shown in the ICH Q10 diagram (Figure 1.1).
Figure 1.1  — ICH Q10 PQS Diagram inclusive of a product lifecycle (updated to enhance 
graphic quality)- (International Conference on Harmonisation, 2008)
Even though KM only found its way formally into the biopharmaceutical sector regulatory guidance in 2005, 
in fact KM concepts had been widely discussed in many other sectors for a quarter of a century or more.  Its 
appearance in an official regulatory guidance document placed additional emphasis on the topic within the 
sector, as noted by one EU regulator: “If something isn’t specifically required by some type of regulatory 
guidance (financial, safety, good manufacturing practice, etc.), even if it’s good for business, it is often difficult 
to drive adoption”. (O’Donnell, K., personal communication, June 3, 2018).
In 2015, the 10 year anniversary of ICH Q10, a two-day Knowledge Management international conference 
KM Dublin 2015 (“Knowledge Management From Discovery to Patient: Enabling Knowlege Flow, Delivering 
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Safe & Effective Products,” 2015), jointly organised by the Irish Regulatory Agency (HPRA), Regulatory Science 
Ireland (RSI) and the Pharmaceutical Regulatory Science Team (PRST), was held in Dublin Castle, Ireland. 
KM Dublin 2015 aimed to drive the knowledge management discussion forward for the biopharmaceutical 
sector. and was themed Enabling Knowledge Flow, Delivering Safe & Effective Products.  This symposium 
attracted over one-hundred and forty attendees.  It was the first of its kind to bring together international 
regulators, life science industry practitioners, academics and KM thought leaders to discuss and explore the 
integration of knowledge management and risk management in the development, manufacture, surveillance 
and regulation of biopharmaceutical and medical device-related health products. 
While it has been over a decade since KM emerged as a Pharmaceutical Quality System (PQS) enabler in 
ICH Q10, there is evidence that  knowledge management is not well understood as a management practice 
because of the considerable focus placed on the science, technology and regulation necessary to deliver the 
sector’s complex array of biopharmaceutical products (Lipa, Kane, & Greene, 2019).  In 2014, the authors of 
this monograph embarked on this research study into the topic of KM, and as the study progressed, so too did 
the level of industry interest in, and discussion on, the topic of knowledge management.
The research examined industry KM methodologies and capabilities in order to gain insights into the level 
of maturity and understanding of KM within the biopharmaceutical sector. In addition, models, tools and 
processes were developed to assist the sector gain greater clarity of the value and merits of KM and offer 
ways to “unlock” the knowledge necessary to deliver the next generation of therapeutics. 
While a thorough literature review found no shortage of academic references related to the broad field 
of knowledge management, a clear gap emerged between academic exploration and practical utilisation 
specifically in the Biopharmaceutical Sector.  The research focused on addressing this gap by examining the 
then  current KM methodologies and capabilities in order to gain insights into how to best utilise existing, 
new, and emerging biopharmaceutical knowledges to realise the ambitions of ICH Q10, stated as, ‘enhance 
the quality and availability of medicines around the world in the interest of public health’, (International 
Conference on Harmonisation, 2008).  In addition, the research endeavored to close the gap between KM 
theory and practice and provide KM practitioners with fit-for-purpose models in the biopharmaceutical 
environment. 
The main output from this research study is a new framework entitled The Pharma KM Blueprint which is 
presented in Figure 1.2 below, and discussed in this monograph. 
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Figure 1.2  — The Pharma KM Blueprint- (Kane, 2018a)
The model is built on the Principle of the need to Manage Knowledge as an asset. It comprises of two 
Frameworks that provide methods of how to Manage Knowledge as an asset, and a KM Diagnostic Tool, 
which can be used to evaluate the Effectiveness of an organisation’s KM approach.  
Subsequent chapters of this monograph discuss the elements of the Pharma KM Blueprint as follows:
•  Chapter 2 - Managing Knowledge as an Asset – addresses the need to value and maintain 
knowledge assets in the same way as physical assets within an organisation
•  Chapter 3 – The Pharmaceutical Product Knowledge Lifecycle Model - addresses the challenge of 
enabling knowledge flow in order to increase visibility, to access and use the product and process 
knowledge assets across the product lifecycle 
•  Chapter 4 - The House of Knowledge Excellence Framework – demonstrates a framework 
developed to implement a systematic KM programme linked to strategic objectives of an 
organisation, incorporating KM practices, pillars (people, process, technology, governance), and 
enablers to support the effective management and flow of knowledge assets. 
•  Chapter 5 – A Knowledge Management Effectiveness Evaluation - provides a practical KM 
diagnostic tool that may be used to identify and evaluate areas of opportunity and to track progress 
on closing knowledge gaps. 
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In addition, the monograph concludes with a final chapter (Chapter 6) in which a high-level overview of 
subsequent research by Lipa is given, building on the research of Kane, into Knowledge Management during 
Technology Transfer.  In that chapter, a framework to improve KM effectiveness at Technology Transfer is 
presented. 
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2. Chapter Two 
 Managing Knowledge as an Asset
This Chapter presents the first element of the Pharma KM Blueprint, namely, managing knowledge as an 
asset. In a seminal publication from 2014 Lipa et al. described the paradox of how the ability to transfer 
and apply knowledge is acknowledged as a competitive advantage, but that however, “knowledge is seldom 
treated like a crucial asset” (Lipa, Bruno, Thien, & Guenard, 2014). This topic was further explored at a 
breakout group led by the authors in the KM Dublin 2015 conference, resulting in a deeper exploration of 
the knowledge asset concept and greater understanding of what constitutes crucial or critical knowledge 
(Kane, 2018b) Participating in this breakout group were key biopharmaceutical industry experts, together 
with thought leaders from the American Productivity and Quality Center (APQC).  
2.1 Valuing Knowledge as an Asset
Linking quality and knowledge management has been, and remains, a foundational component of the mission 
of APQC.  APQC’s founder Jack Greyson was one of the creators of the Malcolm Baldridge National Quality 
Award (MBNQA). The MBNQA recognises US organisations for performance excellence. Not surprisingly then, 
knowledge management is a core capability included in the evaluation process for the MBNQA award, and 
it is in supporting materials for applying for this award that a definition for “knowledge assets” appears. This 
definition of a knowledge asset provides, in the opinion of the authors, the most comprehensive definition of 
knowledge assets in the literature review undertaken for this body of research. This definition and description 
are given below:  
‘The term “knowledge assets” refers to the accumulated intellectual resources of your 
organisation. It is the knowledge possessed by your organisation and its workforce in 
the form of information, ideas, learning, understanding, memory, insights, cognitive and 
technical skills, and capabilities. Your workforce, databases, documents, guides, policies and 
procedures, software, and patents are repositories of your organisation’s knowledge assets. 
Knowledge assets are held not only by an organisation, but reside within its customers, 
suppliers, and partners as well. Knowledge assets are the “know how” that your organisation 
has available to use, to invest, and to grow. Building and managing its knowledge assets are 
key components for your organisation to create value for your stakeholders and to help sustain 
overall organisational performance success.’ (Steel, n.d.)
Building on this concept of knowledge assets, Lim et al. noted, that for organisations to succeed, they ‘have 
to view knowledge as an asset and manage it effectively’ (Lim, Ahmed, & Zairi, 1999, p. S616).
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Based on 25 years of the personal experience of the authors, validated by the themes elicited from the 
industry consultations and discussions at KM Dublin 2015 conference, a key observation was that: 
The biopharmaceutical sector had not yet come to the realisation that knowledge is an 
asset, as demonstrated by the lack of formal processes and/or resources to manage its 
knowledge as an asset. Knowledge assets are not treated as equivalent to physical assets, 
such as plant, equipment or lab bench technologies. 
 
In valuing knowledge assets, the authors considered that, in fact, physical assets and knowledge assets have 
several characteristics in common as follows:
•  Both classes of assets can appreciate or depreciate: Not all knowledge has the same value over 
time. 
•  The more the asset is used, the more value it creates: When a bioreactor is run at high capacity, it 
brings more value to the business than when sitting idle.  Similarly, if a knowledge asset is not used, 
it provides little value to the person who captured and stored it, or to the business.   
•  Both physical and knowledge assets can be traded: For example, in the form of sharing explicit 
knowledge (a report or training programme) or sharing an expert who has deep tacit knowledge 
about a topic within your network. 
•  There is a market value for a knowledge asset: In the case of tacit knowledge, when tacit 
knowledge is needed, and it isn’t available, it is possible (in some cases) to purchase that 
knowledge, such as by hiring experts to troubleshoot a critical utility system, engaging consultants, 
or the addition of knowledgeable/experienced new full-time staff.  Conversely, organisations that 
build up a deep internal knowledge often sell their services to others e.g. in 1991 NNE (Novo Nordisk 
Engineering) began selling their pharmaceutical engineering services to others outside of their own 
company. In the instance of explicit knowledge, it is possible to purchase standards, reports or other 
forms of codified knowledge to enhance the body of knowledge within an organisation. 
 
Dr Nick Milton of Knoco has written on the theme of knowledge assets and describes the traditional field of 
physical asset management as ‘well studied’. He suggests learning opportunities in linking the methodologies 
of physical asset management to knowledge asset management (Milton, 2014). Milton outlines the four 
stages of an asset lifecycle, citing the Asset Management Accountability Framework developed by the State 
of Victoria (AUS), as a starting point to consider when managing knowledge assets,  as in Figure 2.1 below. 
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Figure 2.1 — Four stages of the asset lifecycle (State of Victoria Department of Treasury and 
Finance, 2016, p. 11)
The four stages outlined in the framework include: Planning, Acquisition, Operations and Disposal. Reflecting 
on these stages, the authors suggest in Table 2.1 what this might mean in terms of KM for a biopharmaceutical 
organisation, and posed key questions to address in the four stages for knowledge assets.
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Table 2.1 — Key questions to address in the four stages for knowledge assets
Planning (including strategy and risk assessment)
•  What knowledge is critical? 
•  Where does it fall within the regulatory framework (GLP, GCP, GMP)? 
•  Is it tacit or explicit?
•  What is the risk of losing this knowledge? 
•  Do we have the systems we need to ensure this knowledge can flow to those who need it, when they need it?
Acquisition: process of procurement
•  How will this knowledge be generated? 
•  Will this knowledge creation occur via a business process (e.g. change management, deviation management, 
technology transfer, business development activities)?
•  Will this knowledge creation occur via a technical process (e.g. experiments, technical scale up, lab-testing, 
manufacturing, data analytics/ SPC review etc.)?
•  What mechanisms are available to capture and store this knowledge once created?
Operation
•  Applying the KM lens to this stage requires a focus on capturing knowledge in the flow of work during 
operations. 
•  KM approaches such as Communities of Practice (CoPs) and lessons learned activities, greatly enhance the 
ability to capture and share knowledge assets in the flow of work.
•  For physical assets it is the norm to have dedicated roles for personnel to maintain these assets on a regular 
basis. This maintenance role, or knowledge curation role, is not yet commonplace in regard to knowledge 
assets.
•  While there may be an information technology person responsible for a system that contains explicit 
knowledge, but who maintains the knowledge assets to ensure they are timely, relevant, and accessible?
Disposal
•  Like physical assets, knowledge assets too have an end of life.  
•  Processes should exist to identify and remove knowledge assets that are no longer relevant1:  not only is it 
costly to manage old assets, it also could make it more difficult to find relevant / current assets in a timely 
manner.  
•  As with maintenance, a role should exist to manage the whole lifecycle of the knowledge asset, and that 
includes a systematic process for disposal.
1 Removal of knowledge assets may be subject to records retention policies.
16 A Monograph from TU Dublin Academic Press 2020  
© Paige Kane and Martin Lipa
Advancing Knowledge Management (KM) as an ICH Q10 Enabler in the Biopharmaceutical Industry 
Having presented the rationale that knowledge is an important asset and should be considered on par with 
a physical asset, the next important step forward in knowledge as an asset component of the Pharma KM 
Blueprint explores the concept of critical knowledge. 
2.2 Critical Knowledge
ICH Q10 Pharmaceutical Quality System (PQS) defines the product life cycle stages of a pharmaceutical product 
as: Product Development, Technology Transfer, Manufacturing, and Product Discontinuation. Throughout 
these individual product lifecycle stages a variety of data, information, and knowledge are created and used. 
A plethora of pharmaceutical GxP regulations 2 outline minimum expectations regarding the management 
of the variety of data and information related to product safety and efficacy, as well as manufacturing and 
testing operations.  
As the industry and technology have matured, companies have increased their organisational capabilities 
for capturing and processing their day-to-day data and information. Advances in terms of Continued Process 
Verification (CPV), Statistical Process Control (SPC), smart manufacturing, data analytics, and now even 
artificial intelligence (AI) capability, have all contributed to the growing “data lakes” across the sector.  Indeed, 
Oliver notes that pharma data are doubling every five months and that:
In recent years, the pharma industry has invested heavily in “data lake” style technologies. 
Essentially, capture the data first and hope to find a use for it later. While the amount of data 
captured has increased, we’re still waiting for the outcomes. (Oliver, 2018)
A key question for the authors is what, if any, of this data might be considered critical? 
Furthermore, the authors pondered that if technology is not delivering the desired outcomes, what about 
the people? Are they delivering desired outcomes?  While the 1990’s brought an early focus on the role of 
people in the knowledge creation process (Nonaka & Takeuchi, 1995),  more than 30 years later, despite an 
increasing regulatory attention on the need for effective risk-based decision- making, the biopharmaceutical 
sector is still lagging in terms of unlocking and connecting tacit knowledge across their organisations. One 
wonders how well the sector actually performs in regard to leveraging its knowledge: in short, how well is the 
sector using what it already knows?  
Reflecting on how well the sector is doing in identifying its critical knowledge, one does not need to look 
further than the ISPE Drug Shortages Survey Report (ISPE, 2013, p. 6), where a significant number of 
respondents noted that ‘production system issues leading to drug shortages or near misses were present 
2 (i.e. Good Manufacturing Practices (GMPs), Good Clinical Practices (GCP) and Good Laboratory Practice (GLP) – collectively referred 
to henceforth as “GxP”)
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during technology transfers or product development’. Indeed, Professor Jose C. Menezes, an expert in Quality 
Risk Management from the Technical University of Lisbon, also highlights the lack of “using what we know” 
as a case of institutional amnesia and evidence of why we continue to see repeated FDA 483’s and Warning 
letters3 within organisations: 
“The [biopharmaceutical] industry has no memory. We keep repeating the same mistakes 
again and again.” Prof. Jose C. Menezes. September 16, 2016 ISPE Annual Meeting, Atlanta 
GA USA
An APQC benchmarking report published in 2018 also confirms that the biopharmaceutical sector has been 
slow to adopt KM approaches. It reports that only 4% of biopharmaceutical KM programmes have reached a 
standardised maturity level of “3” or better, in comparison to 18% across all other sectors. (Trees & Hubert, 
2018, p. 50).  In contrast, an earlier, non-pharma specific survey, this time conducted by KPMG, reported that 
79% of respondents believed that KM can play an “extremely significant” or a “significant” role in improving 
competitive advantage (KPMG, 2000, p. 15). For other sectors KM approaches embedded into the flow 
of work have been credited with employee engagement as well as considerable sources of cost savings. 
A specific example comes from El Paso, an oil and gas company, where KM efforts were focused to foster 
expertise within the firm and share technical knowledge across the organisation.  El Paso targeted  first-year 
savings of $500,000, but in fact delivered over $1.2 million in savings in the first year (APQC, 2012b).  
Slow KM adoption also featured in the researchers 2017 ISPE Pharmaceutical KM Survey4, where only 25% 
of respondents indicated that KM was embedded in the way they work.  Therefore, with KM adoption in the 
biopharmaceutical sector clearly lagging behind other sectors, and the blight of an industry-wide case of 
amnesia, one could question if product and process knowledge is delivering value to either our businesses, 
or, more importantly, to our patients.
Arguably, a key challenge inherent in those data and information capture is the conversion of those data and 
information into knowledge, and the identification, retention and perhaps most importantly of all – the use 
of the critical knowledge (that may be explicit or tacit) in order to speed decision-making, enable greater 
insights to support risk management and drive operational excellence through continuous improvement.  
Returning to the development phase of the biopharmaceutical lifecycle, ICH Q8 - Pharmaceutical Development 
(International Conference on Harmonisation, 2009), placed an emphasis on product and process understanding. 
However, it is clear from this research that there are many more sources of organisationally critical knowledge 
3 FDA 483’s and Warning letters are written notices of non-compliance with federal regulations. A Warning letter may be issued for a 
significant infraction and could result in the loss of licensure and other penalties.
4 Although not statically relevant, low participation in the survey may also point towards a general lack of maturity and awareness of 
KM within the sector
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beyond that knowledge which is directly related to the development, or even manufacture, of a given product 
and process, such as patient usage, post-market surveillance, knowledge of business processes, etc. This is 
further discussed in the next section.
2.3 Stemming the Loss of Critical Knowledge
In the opinion of the authors, in addition to product and process knowledge highlighted in the ICH Guidance 
documents and GxP regulations, critical knowledge may also come from sources beyond the traditional “GxP” 
lens. This includes capturing lessons learned, expertise or ‘know-how’ of how things work, whether it be 
sourced as a technical element or an input or output from a complex business process, and even knowledge 
gained from continual improvement programmes and projects.   
The knowledge of how things work and how things get done is also critical to an efficient and effective 
workflow, and often has a direct impact on the ability of the organisation to consistently deliver high quality 
medicines to the patient.  Often times this knowledge is not recognised or valued as ‘critical’ until someone 
leaves their role, or even more challenging, exits the company.  By which point it is difficult or impossible to 
recover or reconfigure the original knowledge asset(s). The challenge of knowledge loss is not specific to the 
biopharmaceutical sector. However, there may be a false sense of security regarding the ability to recreate 
such knowledge within the sector due to the traditional focus on retention of regulated data, records, and 
information.  However, “know-how” often provides the key necessary to unlock the critical knowledge from 
within these retained records.  Without the “know-how”, retained data and information may never progress 
up the hierarchy to be converted into useful knowledge.  Therefore, in the biopharmaceutical sector it is 
important that knowledge retention strategies should never be mistaken for record retention policies and 
procedures.  Knowledge retention is a much broader organisational capability, never more so than when the 
outsourced supply chain is also considered.  Davenport et al. remind us that if you are ‘renting knowledge, 
make sure you take steps to retain it’ (Davenport & Prusak, 1998, p57.).  Supplier Technical Agreements (TAs) 
should, but often don’t, incorporate clauses related to the knowledge that emerges over the course of the 
contractual arrangement with a supplier.
Knowledge mapping is one valuable KM practice that may be utilised to help identify knowledge and its 
relative importance to the organisation. A proven knowledge mapping tool, specifically designed for use 
within the biopharmaceutical sector, has been developed and used successfully by one of the authors of 
this monograph (Kane, 2018b). Finally, knowledge mapping is one of the core KM practices identified in the 
overall House of Knowledge Excellence Model (Kane & Lipa, 2018), which is described in detail in Chapter 4, 
and which is the third element of the Pharma KM Blueprint. 
19A Monograph from TU Dublin Academic Press 2020 
© Paige Kane and Martin Lipa
Advancing Knowledge Management (KM) as an ICH Q10 Enabler in the Biopharmaceutical Industry Advancing Knowledge Management (KM) as an ICH Q10 Enabler in the Biopharmaceutical Industry 
2.4 Conclusion
In conclusion, the authors acknowledge the complications which arise in the biopharmaceutical landscape 
specifically in respect to the regulatory expectations to capture, store, and validate a range of explicit 
knowledge.  As discussed, not all knowledge or content are of equal value or regulatory importance. This 
concept is aligned with the recommendation in the ISPE GAMP© Electronic Records & Signature guidance 
(ISPE Guide, 2005) noting the need for ‘application of appropriate controls commensurate with the impact of 
records and the risks to those records.’  Pragmatic KM guidance in this field also advocates that the manner 
in which explicit knowledge and content is stored and curated5  should be commensurate with the relative 
importance/criticality of that knowledge. 
This chapter has presented the need to manage knowledge as an asset and shown how physical assets and 
knowledge assets have several characteristics in common, including the necessity to have dedicated roles 
for personnel to maintain these knowledge assets on a regular basis. This maintenance role, or “knowledge 
curation” role, is not yet commonplace in this sector.  Chapter 3 will outline the next key element blueprint, 
the Pharmaceutical Product Knowledge Lifecycle (PPKL) Model, which discusses the importance of enabling 
knowledge assets to flow across the product lifecycle.
5 curate something (especially on the Internet) to collect, select and present information or items such as pictures, video, music, etc. 
for people to use or enjoy, using your professional or expert knowledge. Oxford Learners Dictionary online.
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3. Chapter Three 
 Pharmaceutical Product Knowledge  
 Lifecycle (PPKL) Model 
This chapter presents the second element of the Pharma KM Blueprint, namely a Pharmaceutical Product 
Knowledge Lifecycle (PPKL) model, adapted from the product lifecycle presented in ICH Q10.  The motivations 
to develop this knowledge lifecycle are twofold.  Firstly, the terms, knowledge and knowledge management 
(KM) are referenced across ICH guidance documents Q8 -Q11 (International Conference on Harmonisation, 
2012) and in the ICH Q12 (International Conference on Harmonisation, 2019)  in over 200 instances.  Yet more 
specific regulatory guidance setting out the expectations for knowledge does not exist. Without a focused 
discussion on the product lifecycle it is difficult to understand how such knowledge is created, connected 
and utilised across the lifecycle.  Industry consultation undertaken as part of our research identified a specific 
request to better define the relationship between the product lifecycle and KM (Kane, Lipa, & Hubert, 2015).
Secondly, in the context of making product knowledge visible, enabling knowledge flow, and increasing 
availability, the authors believe the lifecycle phases as depicted in ICH Q106 do not represent actual practice 
in the context of knowledge management and knowledge flow.  They therefore offer a re-imagined model to 
emphasise the critical role that knowledge plays in the pharmaceutical product lifecycle. It is the opinion of 
the authors that the very absence of knowledge from the product lifecycle model, depicting how the product 
and process knowledge assets are created and transferred into other organisational knowledge outputs, 
directly contributes to the ambiguity and compartmentalisation of lifecycle knowledge, and greatly inhibits 
the intended benefits sought by the ICH suite of quality documents.
3.1 Product Knowledge – the Regulatory Landscape
ICH Quality guidance issued during the period of 2005-2012 created awareness of risk-based science 
approaches to ensuring pharmaceutical product quality. The ICH Quality guidance documents share common 
expectations of leveraging product and process knowledge as an enabler to effective risk-based science.  
In addressing the need to process post-approval changes in a more predictable and efficient manner, the ICH 
Q12 concept paper was issued in 2014 entitled, Technical and Regulatory Considerations for Pharmaceutical 
Product Lifecycle Management (International Conference on Harmonisation, 2014).  The ICH Q12 concept 
paper identified gaps in realisation of intended benefits.
6 The product lifecycle is depicted in ICH Q10 Annex 2 page 17 (International Conference on Harmonisation, 2008)
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“There is currently a lack of a harmonised approach on technical and regulatory considerations 
for lifecycle management. While the concepts in ICH Q8, Q9, Q10 and Q11 provide opportunities 
for a more science and risk-based approach for assessing changes across the lifecycle, several 
gaps exist which limit full realisation of intended benefits.” 
In November 2019 ICH Q12 was published (International Conference on Harmonisation, 2019) and it focuses 
on established conditions and post-approval changes with modest additional KM guidance.  Q12 highlights 
the following: 
a)  A ‘PQS includes appropriate change management, enabled by knowledge management, and 
management review’
b)  ‘Provisions should be made for sharing knowledge (e.g. in quality agreements and/or contracts) that 
relates to product and process robustness or otherwise informs changes between the MAH and 
relevant manufacturing stakeholders’
c)  In addition to the individual sources of information, there should be a holistic view of quality 
performance for a product or product family.  
Figure 3.1 depicts the diagram from the Q12 which places highlights Knowledge Management as a key 
component of the Change Management process.
 
Figure 3.1 — ICH Q12 - Putting Knowledge Management as a key component of Change 
Management (International Conference on Harmonisation, 2019, p. 19)
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The authors suggest that organisations could greatly benefit from further guidance to assist in forming a 
holistic end-to-end (E2E)7 view of product knowledge assets, similar to the Q12 recommendation for a holistic 
view for quality performance. One path towards further guidance could be achieved if regulatory guidance 
for KM8 was approached in the same way as ICH Q9 was developed for QRM. However, while this route could 
reduce the current levels of ambiguity, the authors conclude that expectations from a regulatory perspective 
could in fact be over-burdensome, and therefore not welcomed by the sector as a whole. 
3.2 The ICH Q10 Product Lifecycle
Returning to ICH Q10, the product lifecycle provides a foundation of shared understanding for the lifecycle 
phases of a medicinal product as shown in Figure 3.2 below. 
Figure 3.2 — ICH Q10 PQS Diagram inclusive of a product lifecycle (updated to enhance 
graphic quality) (International Conference on Harmonisation, 2008, p. 21)
  
The authors suggest that, not only is KM an enabler of the PQS as depicted in the ICH Q10 model, but it is in 
fact fundamental to how the sector creates value for patients and stakeholders since it enables end-to-end 
visibility, flow and availability of what is known about the products.
Although the suite of ICH guidance highlights the importance of capturing and building on product and 
process knowledge, recommendations on how this might be achieved are not included.  Understanding the 
flow between the product lifecycle phases, the range of supporting business processes and the needs of the 
7 E2E refers to the product lifecycle from product development through product discontinuation
8 The authors are not specifically advocating for regulatory guidance for KM – as evidenced in the industry consultation events, any 
guidance, either by industry or regulators would be beneficial
23A Monograph from TU Dublin Academic Press 2020 
© Paige Kane and Martin Lipa
Advancing Knowledge Management (KM) as an ICH Q10 Enabler in the Biopharmaceutical Industry Advancing Knowledge Management (KM) as an ICH Q10 Enabler in the Biopharmaceutical Industry 
myriad of groups involved in capturing knowledge assets can leave organisations in a quandary as to how 
to enhance visibility and utilisation of the behemoth of product and process knowledge gathered over the 
lifecycle.  A lifecycle approach to KM provides a unique value proposition to help an organisation looks end-
to-end at the flow of its knowledge assets, transcending organisational structure, geographies and other 
boundaries. In practice, enabling knowledge flow across the multiple phases of the product lifecycle can be 
very difficult.
3.3 Connecting Product and Process Knowledge 
Product and process knowledge is created constantly through a variety of business processes, dialogues and 
other interactions between colleagues. This knowledge is stored across many different locations (i.e. formal 
and informal repositories and other IT systems) as well as in the heads of subject matter experts.  Returning 
to a quote from O’Dell that “knowledge is sticky’, two challenges were identified by the authors in connecting 
knowledge, the first of which is enhancing the visibility of lifecycle knowledge assets. and the second is 
enhancing the flow of those knowledge assets. These were echoed in the BPOG KM Technical Roadmap 
(BioPhroum Operations Group, 2017) where the team noted: 
The biopharmaceutical community (the industry and its stakeholders) can advance IT tools 
and systems by articulating what knowledge and knowledge flow is, defining organisational 
knowledge flow challenges, developing best practices and biopharmaceutical use cases 
… and creating real-time, networked knowledge management systems throughout the 
biopharmaceutical industry.
The authors, reflecting on the insights gain from the industry consultations and direct experience, summarise 
possible reasons for these challenges as follows: 
•  Guidance is lacking on product lifecycle knowledge lifecycle and the knowledge generated within 
the lifecycle phases and activities
•  The industry recognises there is a problem, but it is difficult to articulate
•  More effectively managing product and process knowledge is a broad issue, and with a clear benefit 
to patients and to the business (reliable supply, access to medicines and lower costs with process 
improvements)
In an attempt to address these challenges, the authors turned to ICH Q10 and suggested a modified version 
of the lifecycle depiction, as discussed in the next section.
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3.4 Reimagining the ICH Q10 Product Lifecycle Model
Every day that the pharmaceutical product is manufactured, more knowledge is created and more is learned 
about the process and the product.  Taking into account the tremendous amount of knowledge that is 
generated across the organisation (internal and potentially external to the Marketing Authorisation Holder) 
across the lifecycle of a product, the authors asserts that:
•  If a primary goal of ICH Q10 is product realisation which requires that an organisation applies the 
best of what it knows (its collective knowledge and experience) in its decision-making for that 
product
And,
•  If every product interaction – whether formal or informal – is viewed as an opportunity to deepen 
the knowledge of the product….
this requires a re-imagination of the ICH Q10 depiction of the product lifecycle.  The authors believe a new 
articulation of the lifecycle could be developed which would better align with the non-linear nature of product 
development, manufacture and knowledge transfer throughout the life of the product. 
The authors propose four areas of opportunity to enhance the ICH Q10 model.  
1.  Technology Transfer could be considered as a Technology and Knowledge transfer activity that 
occurs several times during the lifecycle of a product. (Therefore, remove Technology Transfer as a 
lifecycle phase and represent it is an activity across the lifecycle).
2.  Addition of a new lifecycle phase of New Product Introduction (NPI) to replace the Technology 
Transfer lifecycle phase to cover the initial commercialisation of the product, which is a highly 
“knowledge rich” activity.
3.  Introduce a new activity for Technical Product Support and Continual Improvement across the 
lifecycle.
4.  Introduce a vision for end-to-end (E2E) product visibility and availability, and a methodology for 
transparency of product knowledge throughout the lifecycle. 
Based on these enhancements, the authors propose the following Pharmaceutical Product Knowledge 
Lifecycle (PPKL) Model that incorporates key knowledge generating activities and sets the stage for improved 
articulation, visibility and availability of product and process knowledge.  
This new model is shown in Figure 3.3.
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Figure 3.3 — Pharmaceutical Product Knowledge Lifecycle Model (PPKL) – research output Kane 
2018
3.4.1 Reimagining the ICH Q10 Product Lifecycle Model - Technology Transfer
The Technology Transfer (TT) phase of the product lifecycle is of particular importance when managing 
product and process knowledge.  ICH Q10 emphasises that the goal of technology transfer is to:
Transfer product and process knowledge between development and manufacturing, and 
within or between manufacturing sites to achieve product realisation.
According to ICH Q10 ‘This [technology transfer] knowledge forms the basis for the manufacturing process, 
control strategy, process validation approach and on-going continual improvement’.  With that description 
in mind, the authors suggest that a more accurate description of this critical activity would actually be of 
Technology and Knowledge Transfer.  This is because, tacit knowledge transfer is frequently undervalued and 
underestimated by the technical teams managing the technology transfer project and, in the experience of 
the authors, a frequent cause of failure and of on-going process-related problems post-transfer.
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On the specific topic of Technology Transfer there are several sector guidance documents as listed below:
•  ISPE: Good Practice Guide: Technology Transfer [Third Edition] (ISPE, 2018)
•  PDA: Technical Report No. 65: Technology Transfer (PDA, 2014)
•  NIHS Japan: Guideline for Technology Transfer (NIHS, 2005)
•  WHO:  WHO Guidelines on Transfer of Technology in Pharmaceutical Manufacturing (World Health 
Organization, 2011).
These guidance documents describe best practice and recommendations regarding technology transfer 
(TT) activities. However, there is little reference to, or guidance provided relating to, the tacit knowledge 
required for the success of the transfer (Lipa, Kane, Greene 2019). Although guidelines outline recommended 
documents and explicit knowledge assets that should be considered in the transfer process, the tacit knowledge 
about the process, which is critical and difficult to characterise and capture, receives little focus.  Typically, 
a small number of technical experts are sent from the sending site to the receiving site to teach, guide, and 
troubleshoot for a short transitional period of time in order to share their knowledge of the product and 
process, and to aid a successful transfer.  Given the time and budget pressures that are often present during 
this initial start-up phase for a new product introduction at the receiving site, the co-ordination of these 
expert resources and the quality of the contact they have with the final commercial operations team is often 
less than optimal.  In many cases their time is spent assisting in the set-up of the equipment and/or process 
to assist the project team to meet key project milestone, such as qualification and validation activities. Little 
time is left for training and coaching the new team responsible for commercial production of the product(s) 
post-handover.
The authors suggest that Technology Transfer (TT) is one particular area that could benefit from a formal set of 
KM practices and tools to systematically capture the critical tacit knowledge necessary to support successful 
technology transfers, with very real potential to benefit the organisation by reducing operational costs and 
resources post-transfer. Work is on-going on developing these practices, and Chapter 6 of this monograph 
presents some outputs of early research in this area.
Another misunderstanding that the authors have sought to address with the adaptation of the product 
lifecycle model is the belief that “Technology Transfer” is a discrete phase over the life of a typical product. 
In fact, throughout the life of any given product there most likely will be multiple technical transfers. Informal 
benchmarking9 within the expert focus groups and KM Task Teams has observed that, for small molecule 
products one could expect four or more TT events as the company continues to optimise production and 
minimise costs over the product lifecycle.  Indeed, technology transfers may be on-going throughout 
the manufacturing phase and product discontinuation phases as products move to other nodes in the 
manufacturing network, are outsourced to third party partners, or the manufacturing site is acquired by 
9 Formal benchmarking of number of Technical/Knowledge transfers in relation to capture of tacit knowledge could be an opportunity 
for future research.
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a new organisation (CPhI Pharma Insights, 2016).  This phenomenon is illustrated on the adapted lifecycle 
model by showing multiple TT chevrons occurring throughout the product lifecycle in Figure 3.3 above.
Furthermore, technology transfer (TT) for a medicinal product typically involves multiple activities: transfer 
of the active pharmaceutical ingredient (API) or drug substance (DS), transfer to the drug product (DP) or 
fill/finish (FF) facility, as well as the transfer of the analytical methods to the respective testing facilities. 
The last TT activity is the final transfer of all product knowledge to an archive facility when the product is 
scheduled to be discontinued. This is highlighted on the PPKL Model, shown in Figure 3.3 with a final chevron, 
acknowledging this transfer in the product discontinuation lifecycle phase. 
The biopharmaceutical sector is not alone in addressing the challenges to transfer critical knowledge across 
organisational boundaries.  In 2012, APQC, at the request of 15 organisation across multiple industries, 
conducted research to seek out best practices in improving the flow of knowledge during process development 
(APQC, 2012a).  Table 3.1 presents four high level knowledge flow best practices and associated sub-activities, 
identified by this APQC research, for organisations to consider.
Table 3.1 — APQC best practices of improving the flow of knowledge during process development 
(APQC, 2012a)




a)  Align process development knowledge capture efforts with key 
business drivers.
b)  Link process development knowledge capture and transfer efforts to 
existing improvement methodologies or principles.
c)  Embed knowledge capture and transfer activities into the process 
development stage-gate process.
d)  Communicate in the language of your “customers.”
2.  Develop an effective 
process to capture 
and transfer process 
development 
knowledge
a) Integrate a robust lesson learned process into process development.
b) Leverage existing groups to guide and vet knowledge.
c)  Accelerate process development knowledge capture and transfer 
with targeted events.
d)  Distinguish among types of process development knowledge to 
capture and transfer.
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Table 3.1 — APQC best practices of improving the flow of knowledge during process development 
(APQC, 2012a)
3.  Create organisational 




a)  Establish explicit governance and accountability for process 
development knowledge capture and transfer.
b)  Capture internal customer insights by partnering with business units.
c) Create opportunities for leaders to learn from each other.
d)  Adopt change management principles and engage people to foster 
organisational support.
e)  Use trained change agents.
f)  Build and maintain a centralised, searchable repository for critical 
process development knowledge.
4.  Continually review 




a)  Enlist and engage process development stakeholders to continuously 
enhance knowledge capture and transfer efforts.
b)  Use leading and lagging indicators to monitor the programme’s 
impact over time.
These strategies identified by APQC could benefit the biopharmaceutical sector if used to complement the 
industry-specific guidelines that address pharmaceutical products such as, control strategy, facility fit, process 
qualification and analytical methods, to name but a few.  The authors believe that, in particular, the concepts 
identified above such as, ‘embed knowledge capture and transfer activities into the process development stage-
gate process’ and ‘build and maintain a centralised, searchable repository for critical process development 
knowledge’, would be particularly beneficial to the success of the overall transfer process. 
Returning to the APQC recommendations for improving the flow of knowledge in the Product Development 
phase, and acknowledging the impact of the diversity of sites, systems and culture, the specific recommendation 
of ‘Communicate in the language of your customers’, is crucial when crossing internal or external organisation 
boundaries.  In addition, ICH Q12 states: 
‘Provisions should be made for sharing knowledge (e.g., in quality agreements and/or contracts) 
that relates to product and process robustness or otherwise informs changes between the 
MAH and relevant manufacturing stakeholders (research and development organisations, 
manufacturers, CMOs, suppliers, etc.). ‘(International Conference on Harmonisation, 2019,  
 p. 31)  
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However, this assumes that effective and efficient business processes for knowledge capture and curation 
related to the product and process already exist at the sending site, and that the receiving site has established, 
effective KM processes which stand ready to receive this knowledge as part of the transfer.  
Finally, to complete this element of the lifecycle, the reimagination of the ICH Q10 product lifecycle offers an 
adapted Product Knowledge Lifecycle (PPKL) Model, which replaces the phase formerly entitled Technology 
Transfer with a phase entitled New Product Introduction (See Figure 3.3).  This phase is intended to depict 
the initial and finite activities specifically related to the first instance of commercialising of given product, 
which is considered a special case of Technology Transfer.  The first transition from Product Development into 
Commercial Manufacturing, with the introduction of a new approved product, presents both challenges and 
opportunities for an organisation, the success of which hinges on the ability of that organisation to create, 
capture, communicate and curate new knowledge about that product.  
3.4.2 Reimagining the ICH Q10 Product lifecycle Model –  
 Technical Product Support and Continual Improvement
The next element of the adapted lifecycle model the authors addressed was the introduction within the 
model of an end-to-end (E2E) workstream entitled, Technical Product Support and Continual Improvement.
During the lifecycle of a product, the organisation will continue to learn and build knowledge about the 
respective product.  This can occur during New Product Introduction, and on-going Commercial Manufacturing, 
through a variety of Technology Transfer activities.  In addition to this, learnings may arise as a result of 
planned and unplanned activities such as:
•  enterprise resource planning techniques established or updated to plan the shop floor workflow 
necessary to execute a batch,
• learnings from deviation resolution or product/ customer complaints,
•  additional studies for process improvement and optimisation.  
The authors suggest an E2E workstream of Technical Product Support and Continual Improvement which 
begins at the New Product Introduction phase when the manufacturing process is locked in order to perform 
technology transfer to the initial receiving site.  These support and improvement activities continue across 
the product lifecycle until the product is discontinued.  When, it should be noted that although the product 
may no longer be manufactured, expertise and knowledge regarding the product and process may still be 
needed for activities such as product complaints, and to inform next-generation product development. 
If a formal process is used to capture, collate and curate the critical aspects of product and process knowledge 
gained from the on-going process verification activities, such as process trending or SPC activities, CAPAs, 
annual product quality reviews (APQRs) and change management oversight, the knowledge will most likely 
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reside in an array of different business process systems, IT repositories and even the personal computers 
belonging to subject matter experts. Further contributing to the “knowledge island” or “silos” issue raised 
during the industry consultation research activities.
This Technical Product Support and Continual Improvement element of the adapted lifecycle is designed 
to purposefully included to provide greater E2E knowledge transparency in order to enable enhanced E2E 
knowledge flow.
Without knowledge transparency (or visibility of the knowledge assets) there can be no knowledge flow. 
Without knowledge flow there can be no use of that knowledge. The consequence for the organisation of 
ineffective transparency and visibility of the knowledge assets is an ineffective Pharmaceutical Quality System 
(PQS).  This can result in grave consequences for the patient and the business. 
The acknowledgment of the rich product and knowledge generated across the product lifecycle is highlighted 
in ICH Q8- Q12. However, as previously noted, the specific knowledge ‘types’ are not easy to identify in a 
concise way. 
A review of the literature identified two specific examples of organisations seeking to make their product 
knowledge visible across the product lifecycle, not by using a complex information technology solution, 
but by introducing a standard business processes that catalogues or indexes product knowledge assets as 
the knowledge is created.  Genentech Roche’s (Reifsynder, Waters, & Guceli, 2018) product knowledge KM 
practice is outlined as the Product History File (PHF) and Pfizer (Kane & Brennan, 2014) describe a formal 
business process called the Process Understanding Plan or PUP.  The PUP is a business process that Kane was 
involved in developing, in conjunction with other colleagues in Pfizer.  One key element common to these two 
business processes is the inclusion of roles and responsibilities for creation and maintenance of the product 
and process knowledge assets. However, dedicated roles for E2E preservation and curation of product and 
process knowledge are not be well defined across the industry, and this is significant area of opportunity for 
the sector. To labor the point, when something is considered everyone’s responsibility, it is actually no one’s 
responsibility.  Returning to the key principle discussed in Chapter 2 of this monograph that knowledge for 
the biopharmaceutical sector must be valued and managed in the same way that physical assets are managed 
in the sector, development of these dedicated KM roles to enable stewardship of the knowledge assets is 
crucial.
Benefits of E2E product knowledge availability and the rationale for implementing KM processes extend 
beyond the articulation of KM in ICH Q10. Improvement of operational effectiveness is recorded as one of the 
top drivers for implementing KM – within and outside of the biopharmaceutical sector (Knoco, 2014, 2017).  It 
should be noted that the business need for product and process knowledge may extend beyond the lifecycle 
phase of product discontinuation, as knowledge of the product may have value beyond any regulated record 
retention requirements to inform learnings of future and existing marketed products.
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A future topic of research could be  the development of a practical KM practice or methodology to deliver 
greater transparency of product knowledge across the product lifecycle, conceptually a Product Roadmap 
that would live with the product across the lifecycle as a map of existing and necessary knowledge assets, 
enabling greater transparency and therefore flow to those responsible for the product from development to 
discontinuation. 
3.5 The Pharmaceutical Product Knowledge Lifecycle (PPKL) Conclusions 
In summary, the authors in this chapter present a novel Pharmaceutical Product Knowledge Lifecycle (PPKL) 
Model as the second element of the Pharma KM Blueprint. The model is offered to encourage those responsible 
for the development, manufacture and distribution of biopharmaceutical therapies to think differently about 
the knowledge that is created during the lifecycle of a product.  The PPKL Model proposed is an adaptation 
or reimagination of the ICH Q10 Product Lifecycle published in 2008 and incorporates the following novel 
features:
•  The model highlights the vision for end-to-end (E2E) product and process knowledge asset visibility, 
transparency and availability in order to enable knowledge flow of critical knowledge to those that 
need it throughout the product lifecycle.    
•  The model includes the addition of a new lifecycle phase of New Product Introduction (NPI) to 
replace the Technology Transfer lifecycle phase. 
•  The model highlights that Technology Transfer is an activity that may occur multiple times across the 
product lifecycle. 
•  The model includes the addition of a new E2E process to capture the Technical Product Support and 
Continual Improvement activities that occur across the product lifecycle.
To further develop the Pharma KM Blueprint, Chapter 4 will next introduce the House of Knowledge Excellence 
(HoKE) Framework, as a strategic and a programmatic approach to managing knowledge in organisations. 
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4. Chapter Four 
 The House of Knowledge Excellence (HoKE)
This Chapter presents the third element of the Pharma KM Blueprint, namely the House of Knowledge 
Excellence (HoKE) Framework.
The HoKE framework provides an opportunity to define what the authors mean by Knowledge Excellence and 
how it exceeds the mere management of knowledge.   “Knowledge Excellence” is not simply the application 
of a series of discrete knowledge solutions, or the provision of sets of tools, but rather it is about enabling 
and sustaining knowledge-focused business capabilities. The essence of the House of Knowledge Excellence 
Framework offers a holistic, programmatic approach to implementing KM founded on the four pillars of 
People, Process, Governance and Technology, in order to enable practical approaches to get knowledge to 
flow.  HoKE requires a deep understanding about “how” work gets done on a day-to-day basis and how best 
to influence the behaviours of the employees or knowledge workers within the organisation. Employees must 
be encouraged and enabled to think and act differently in how they seek and share knowledge.  
The authors propose that the rationale for pursing capabilities in knowledge management should not be to 
merely satisfy regulatory expectations, as highlighted in ICH Q10, but to deliver value to the business and 
ultimately to the patient.  
The genesis of the House of Knowledge Excellence (HoKE) Framework stems from the industry consultation 
sessions in which biopharmaceutical sector KM practitioners highlighted the need to further define and 
visualize KM Strategy and KM Program design, as well as to define practical KM approaches.  As informed by 
a literature review, very few biopharmaceutical organisations have implemented a programmatic approach 
to knowledge management to date. Where organisations are pursuing KM, it often starts out as a discrete KM 
project to address a specific knowledge gap or business driver.
The House of Knowledge Excellence (HoKE) is a practical approach that organisations may use to assist in 
either the development of a KM strategy, the roll out of a holistic KM programme, or in the identification of 
KM approaches that may benefit biopharmaceutical companies (Kane & Lipa, 2018).  The title of the HoKE was 
specifically chosen to reflect the need to move beyond the compliance expectations of managing knowledge 
to realise the true business benefits of being excellent in the capture, curation and use of our knowledge. 
The framework was developed by the authors and published in 2018 as a book chapter entitled The House 
of Knowledge Excellence – A Framework for Success (Kane & Lipa, 2018). The HoKE framework is presented 
below in Figure 4.1, however, for more detail, it is recommended that readers consult the complete chapter 
in the published book.
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Figure 4.1 — House of Knowledge Excellence (HOKE) -(Kane & Lipa, 2018, p. 219)
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5. Chapter Five 
 Knowledge Management  
 Effectiveness Evaluation (KMEE) 
This chapter presents the fourth and final element of the Pharma KM Blueprint, namely the Knowledge 
Management Effectiveness Evaluation (KMEE).  The KMEE is an innovative diagnostic tool developed by the 
authors to facilitate a structured evaluation of the effectiveness of how an organisation uses its knowledge. 
The KMEE was designed to help identify actionable items that functional groups could undertake to improve 
the management of their knowledge and to identify potential opportunities (i.e. gaps) for improving the 
availability, access, visibility, flow and use of the knowledge assets required by the members of their group 
in order to be able to conduct their day-to-day work efficiently. The development of this diagnostic tool was 
inspired by analysis of data received from a KM maturity evaluation exercise executed using the APQC KM 
CAT™  – KM Capability Assessment Tool within the one of the author’s organisations. Following the completion 
of the APQC KM CAT™ evaluation, the author recognised that while the APQC KM Capability Assessment Tool 
worked well at a business level, it did not provide enough granularity to evaluate the needs at a frontline team 
or shop-floor level.  
While a “one size fits all” evaluation methodology might be considered optimal in application, customising the 
scoring tool has proved important to create the practical linkages between KM theory and practice. Evaluating 
organisational KM maturity scored using the KM-CAT™ tool for a large organisation provides valuable business 
level information, and when coupled with the KMEE tool executed at a functional group level, deep insights 
into the overall effectiveness of the organization’s KM capability right down to the frontline team members 
are captured. This chapter provides a real-world example of the application of the KMEE evaluation tool 
within one of the author’s organisations (a large multinational biopharmaceutical company). 
5.1 Evaluating Knowledge Management Maturity,  Knowledge Flow,  
 and Improvement 
Measuring KM maturity is an important element of assessing the success of any effort to improve KM practices. 
Learning from a core business performance principle: ‘If you are not measuring, you’re not competing’ (Snee, 
2006). This is also true when evaluating use of knowledge assets.  However, measurement alone is not enough 
to drive improvement. Measuring the right things is critical to the success of any organisational change effort. 
It is worth reviewing an observation on KM Maturity by Kruger and Snyman.
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It is clear that the inability to bridge the gap between theoretical propositions and practical 
usability is not only hindering knowledge management practitioners from successfully 
assessing the level of knowledge management maturity reached within organisations but, 
more importantly, is making managers lose faith in knowledge management as a strategic 
enabler. (Kruger & Snyman, 2007)
The authors have direct experience of using the APQC KM CAT™  – KM Capability Assessment Tool in multiple 
instances within two large biopharmaceutical companies and one biotechnology industry collaboration 
group.  It was found that in practice, the KM CAT™ tool was informative to assess KM Program and high-level 
organisational maturity. A key benefit of using the KM CAT™ is the ability to benchmark the maturity value for 
a given organisation against the extensive APQC data set (both sector centric indices and industry agnostic 
indices).  However, when executed at the divisional level, the KM CAT™ proved difficult to translate the findings 
from the maturity assessment into specific actions for individual teams.  A helpful analogy to consider is how 
a global stock market index can be used to describe the overall performance of a sector but provides little 
insight into the performance of individual businesses included in the index average. This reflection, and the 
need to close the ‘knowing – doing gap’, lead the authors back to the Kruger and Snyman observation above. 
Diving deeper into the maturity assessment, the challenge with the KM CAT™ was multifaceted. Evaluation of 
the feedback from participants revealed the following:
1.  The structure and taxonomy used within the KM-CAT™ question-set required deep experience 
with the tool to “translate” the questions for participants. Participants were unfamiliar with much 
of the KM specific terminology, for example when questioned about access to a Expertise Locator 
KM Tool (a searchable tool to help them find an expert in a subject area within their organization) 
participants were not aware that a staff contact database system available on their internal company 
intranet was in fact an Expertise Locator tool. 
2.  Participants felt many of the standard benchmarking questions were not relevant to them as 
individuals or to their teams (e.g. details related to overall budget for KM, leadership sponsorship 
for KM etc.), and therefore could not answer those questions with confidence.   
3.  Participants felt that many capabilities which they actually demonstrated were not recognised or 
reported through the KM-CAT™   tool due to the scoring methodology i.e., groups felt they were 
acknowledged for progress or unless all the capabilities within a given maturity level were met.
4. Benchmarking results were not presented at a level that the individual teams felt they could 
meaningfully action.
5.  KM Advocates10 within some teams were frustrated that the level of assessment didn’t clearly 
identify practical examples of how individual groups could improve (as related to item 4 above). 
6.  The full assessment took multiple hours to complete: it was too time-consuming with limited 
“relevance” in the view of participants at lower level teams.
10 KM Advocates were employees within a functional team passionate about KM approaches who helped their team avail of enterprise 
KM tools and approaches.
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Upon consideration of the feedback, the authors considered one simple solution would be to take the KM-
CAT™ deeper in to the organisation, however they did not believe the sentiments presented around relevance, 
terminology, and reporting detail would be addressed by the KM-CAT™ alone. Based directly on this feedback, 
they sought to develop a KM maturity evaluation tool that was:
•  Relevant to smaller teams/ functional groups, focusing on items within their control
•  Could be used as a baseline to further measure specific team capability 
•  Was capable of articulating gaps within the teams
•  Included a scoring template that could recognise the achievement of individual capabilities 
•  Included a scoring template that enabled prioritising and closing identified gaps 
•  Could be administered by a local KM advocate, and did not require an SME from the KM Program 
Team to “translate”.
Before discussing the details of the resulting KMEE Diagnostic tool developed by the authors, it is first useful 
to understand the key features and scoring mechanisms embedded within the APQC KM-CAT™ tool.
5.2 APQC’s Knowledge Management Capability Assessment Tool™ (KM-CAT™)
According to APQC the APQC’s Knowledge Management Capability Assessment Tool™ (KM-CAT™) helps 
an organisation assess its capabilities and maturity in knowledge management (KM) and to focus its KM 
investments to produce the highest return on value. This assessment maps the current ‘as-is’ state of KM and 
the knowledge flow processes within an organisation in order to: 
•  Measure the current maturity of the enablers and infrastructures employed,
•  Evaluate the current status of knowledge flow processes and supporting approaches,
•  Set an objective for the improvement of business processes through the flow of knowledge,
•  Guide the evolution of organisational change, and
•  Compare or benchmark with similar efforts of other internal units or external organizations.
The KM-CAT™ is divided into four major sections with subcategories as shown in Table 5.1 below.
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Table 5.1 — APQC KM-CAT™ - Four major sections with subcategories
Strategy
•  Objectives




•  Governance structure and roles
•  Change management
•  Communication
Process
•  Knowledge flow process
•  KM approaches
•  Measurement
Content and Information Technology
• Content management
•  IT processes and tools
Within each section, capabilities are described ranging in maturity levels 1-5.  APQC describes the levels of 
Maturity (APQC, 2010) as:
•  Level 1 — an organisation is aware that it has a problem retaining and sharing knowledge.
•  Level 2 — initial knowledge approaches are in place. The focus is on helping localised knowledge 
flow and adding value. 
•  Level 3 — the knowledge flow processes are standardised, and the focus is on meeting business 
requirements, achieving results, and developing a supporting infrastructure. 
•  Level 4 — the KM efforts align with the organisation’s business objectives and the focus is on 
leveraging core knowledge assets across the enterprise.
•  Level 5 — KM practices are embedded in key business processes and the focus is on the competency 
of the business.  
Scoring of the KM-CAT™ requires that all capabilities within that level must be demonstrated in order to 
achieve a score in the level (e.g. level 1, 2, 3 etc.). In addition, all capabilities associated with any given level 
below the current maturity level must also be demonstrated within the organisation in order to be considered 
to have achieved that level. To further explain the scoring, an excerpt of the KM-CAT™ KM Approaches & Tools 
section is shown in Table 5.2 below:
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Standard methods are used to capture and retain valuable knowledge.
The organization uses replicable knowledge flow processes and KM approaches.
Enablers and infrastructure support knowledge flow process.
KM methods and tools are available to knowledge workers on demand.
KM maturity and capabilities are assessed.
A KM "resource center" is established, including KM reading materials, case studies, 
and presentations.
2
Some KM approaches to support knowledge flow (e.g., communities of practice, 
knowledge capture, lessons learned, and expertise location) are implemented in parts 
of the organization.
Knowledge maps for each initial KM focus area identify content and knowledge needs/
gaps.
Core business processes that require enhanced knowledge flow are identified.  
1
Story-telling and one-to-one exchanges are the primary approaches used for knowledge 
transfer. 
For example, three capabilities are required to be in place in order to meet the criteria for Level 2 for this KM 
Capability assessment.  All three capabilities within Level 2 must be met, in addition to the single capability 
required at Level 1. If the Level 1 capability is not demonstrated, even if all Level 2 capabilities were achieved, 
the organisation would not score KM maturity at Level 2. 
The authors recognise that, while there are many positives with the KM-CAT™, the scoring methodology and 
process is particularly challenging when trying to evaluate and engage functional teams. While the overall 
rationale for scoring11 is sound, the results as presented by the APQC methodology, are not particularly 
insightful at the function level.  Table 5.3 describes challenges and potential solutions the authors considered 
when designing an updated tool.  
11 Scoring methodology is similar to that of Malcolm Baldrich Quality Award, in which APQC was also involved in the development
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Table 5.3 — Opportunities for KM-CAT™ Tool
KM-CAT™  Challenge Potential Solution
Administration of KM-CAT™  questions 
required deep experience with the tool 
to “translate” for participants
Develop a set of customized questions 
maintaining intent of the KM-CAT™ to retain the 
ability to benchmark with APQC 
Questions around strategy and 
resources and were not relevant to most 
participants 
Identify questions relevant to individual teams 
working in the business (not the KM Team)
All capability in a level must be met to 
get credit for them
Devise a methodology score progress within a 
maturity level to credit each capability met
Scope of KM-CAT™  was too high level to 
enable local teams to understand where 
they fit
Design the tool that it is relevant for individual 
teams yet still maintains integrity, to enable 
rolled up to the KM-CAT™  
Assessment too long
Identify relevant/applicable capabilities for 
functional teams (items within their control) in 
order to simplify
5.3 Need for a supplemental tool for localised functional KM Assessments
While acknowledging that the KM-CAT™ is suitable for measuring overall organisation and KM programme 
maturity /capability, the authors endeavored to create a focused capability diagnostic tool aimed at smaller 
groups/teams such that it: 
1)  Is customised to reflect specific KM tools and processes within the organisation – drives engagement 
at the individual or team level, and not at the KM Programme level. In addition, the customisation 
aids in developing specific action plans.
2) Is scored to clearly acknowledge all capabilities met within levels, with “credit given” even if not 
all capabilities within a given level have been achieved.  Participant feedback found this very 
frustrating.
3) Provides visual results of specific scoring to enable future progress tracking.
4) Provides a mechanism to prioritise gaps identified. 
5) Provides templates for reporting and action planning. i.e. Pre-populated templates with specific 
recommendations, outlining the benefit to the organisation for closing the gap. 
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5.4 Development of the Knowledge Management Effectiveness Evaluation  
 (KMEE) Tool:
The development of the KMEE tool included the following steps.
1) Each capability within the APQC KM-CAT™ tool was first reviewed for relevance for each individual 
group – e.g. a smaller part of the organisation whose primary responsibly was supporting product 
realisation and continual improvement, and did not have a responsibility for developing the overall 
Divisional KM programme.  
2) Capabilities deemed relevant from the APQC KM-CAT™ tool were then supplemented with specific 
organisational “translations” of the capability to clarify the requirements and relevance.
3) Capabilities were organised via the sections and sub-sections of the original APQC KM-CAT™ tool, 
and each of the criteria for the maturity level were also included.  
Note, the version of the APQC KM-CAT™ tool that was leveraged for further development contained 4 Sections 
and 12 sub-sections and 151 individual capabilities.
After review and evaluation of the full APQC KM-CAT™ assessment tool, the authors determined that 28 
individual capabilities arranged into 3 sub-categories/focus areas would be most suited to individual groups 
within the biopharmaceutical organisation seeking to improve its KM maturity and knowledge flow.  
These are shown in Table 5.4 below: 













Content and Information 
Technology
(IT1) Content management/ 
Information Technology processes 
and tools
5
Each of these sections have sub-categories which have been labeled as in the APQC Tool (PP3, PP4, PR1, PR2, 
PR3, IT1).  Note, that in the full APQC assessment there are additional sub-categories not represented in 
the KMEE. Within each of the KMEE levels of maturity (levels 1-5) the number of associated capabilities are 
identified, are shown in Table 5.5:
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Table 5.5  — Capability description within maturity levels depicted






The modified KMEE evaluation tool is now shown in the next three tables. Table 5.6 related to Content and 
IT capabilities, Table 5.7 evaluates People capabilities, Table 5.8 evaluates Process and Knowledge Flow 
capabilities.




KMEE Function Specific  
Description of Capability
1





management processes are 
in place.
General document management processes are 
in place. What are they?
1





technologies (IT) and tools 
are leveraged and used 
where possible.
Existing KM information technologies (IT) and 
tools are leveraged and used where possible 
(i.e. expertise locator, XX discussion boards, 
XXX product knowledge system XXX, Enterprise 
Search) 
2




Content is identified and 
organised at business unit or 
domain.
Knowledge/Content is identified and organized 
at a group level or workflow level (may be 
sporadic)- list the methodology
3




Standardized taxonomies for 
classifying core knowledge 
assets exist.
Your group uses a standard naming convention 
for storing content - what is the methodology?
3






Content management workflows are 
standardized. All colleagues know where to store 
their content on shared spaces with supporting 
document management practices - list the 
practices
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Table 5.7  — KMEE People Capabilities
Level Category APQC Capability Description





Current state assessment of 
successes and problems in 
knowledge sharing include 
the identification of potential 
barriers and competing issues 
impacting knowledge flow 
required for business results.
Have you done an assessment to gauge KM 
issues in your group/site? If so, do you know 




Education and training plans 
are in place to support initial 
KM projects.
All colleagues in your group have been trained 
on the core KM approaches for all GTO - i.e. 
expertise locator, XX discussion boards, 
Enterprise Search, Lessons learned portal, 
enterprise search. And if part of colleague’s 
roles- the product knowledge system XXX, 




Barriers to sharing and using 
knowledge are identified and 
addressed.
Your group has identified barriers to sharing 
and using knowledge and have addressed them 
(with help from the KM team if needed) - list 




Accountability is expanded for 
knowledge flow processes and 
approaches.
Groups outside of the official KM group are 
working to ensure that knowledge flows 
across the site/business (e.g. collaborative 





KM advocates are in place 
across the enterprise.
Colleagues who are responsible for advocating 
for KM projects / approaches are in place in 





Formal recognition is given for 
KM efforts, success, and lessons 
learned.
Formal recognition is given for KM efforts, 
success, and lessons learned within your group 




KM training is provided to new 
hires to help make KM a part of 
the culture.
Overview of the division/group specific KM 
approaches are provided to new hires or 
colleagues that have joined the organisation 




KM advocates have 
accountability for KM results.
Colleagues responsible for advocating for KM 
projects / approaches (site for sites and center 
groups for center) have accountability/ success 
for group KM approaches in their performance 
objectives
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Table 5.7  — KMEE People Capabilities
Level Category APQC Capability Description





KM is aligned with talent 
management and leadership 
development.
Talent management processes leverage KM 
approaches/ processes (e.g. current online 
profiles, expertise locator) to ensure that talent 
& experience is visible to all colleagues- also 
leaders leverage the expertise locator/profiles 
to ID potential diverse candidates for new 
development opportunities/ roles
2 People: (PP4) 
Communication
KM advocates discuss the 
value of KM to the business 
with senior leaders and key 
stakeholders.
KM advocates (site or programme colleagues) 
have been identified for your group and engage 
with leaders and managers to discuss the KM 
approaches/ projects and value to the group
3 People: (PP4) 
Communication
Success stories from initial 
KM projects are broadly 
communicated.
Has your site or group communicated any 
success stories levering KM, if so what or what 
are the opportunities?
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Table 5.8  — KMEE Process and Knowledge Flow Processes
Level Category APQC Capability Description
KMEE Function Specific  
Description of Capability
2 Process: (PR1) 
Knowledge 
Flow Process
Stabilized knowledge flow 
processes are embedded in KM 
approaches e.g., Communities 
of Practice, Lessons Learned, 
After Action Review, etc.
List the processes that enable knowledge to flow 
across groups, projects, etc. Examples could be 
Lessons Learned, CoPs, discussion boards
3 Process: (PR1) 
Knowledge 
Flow Process
Standardised knowledge flow 
processes are used across 
multiple instances or situations.
What are the standardised processes to enable 
the flow of knowledge across multiple groups in 
the organisation 
4 Process: (PR1) 
Knowledge 
Flow Process
Knowledge flow processes are 
embedded in core business 
processes and domains. 
Your group us leveraging KM concepts of 
knowledge flow and capture into the design of 
"systems", business processes (e.g. collaborative 





Knowledge maps for each initial 
KM focus areas identify content 
and knowledge needs/gaps.
Your group has participated in a Knowledge 
mapping exercise and gaps have been identified. 




Core business processes that 
require enhanced knowledge 
flow identified.  
Your group understand what core business 
processes would benefit from applying the "KM" 




Standard methods are used 
to capture and retain valuable 
individual knowledge
We have methodologies (plural) for capturing 




KM maturity and capabilities 
are assessed.
KM maturity and capabilities are assessed using 
the Knowledge management Effectiveness 




KM competency maps exist for 
individual roles and/or jobs.
Individual roles / jobs within the group clearly 
state what knowledge is needed and generated 




KM approaches, methodologies 
and tools are integrated 
with process improvement, 
organizational development, 
and learning approaches.
List the KM approaches, methodologies and 
tools you use that are integrated with process 
improvement, organisational development, and 
learning approaches e.g. when we do an OpEx 
project, innovation project, troubleshooting, 




KM becomes a "core 
competency" of the 
organisation.
What is the evidence that KM is a "core 
competency" and competitive advantage of your 
group
1 Process: (PR3) 
Measurement
An assessment of critical 
knowledge in current business 
processes / domains is 
conducted.
Has your group participated in a Knowledge 
Mapping exercise?  If so,  have you implemented 
the remediation plan? 
2 Process: (PR3) 
Measurement
Local KM activity measures are 
in place and used.
KM Advocate or group leader measuring/ 
monitoring the use of KM activity within the 
group e.g. the participation in discussion boards 
‘X’, the updating of online profiles, etc. - list the 
examples
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5.4.1 Scoring Methodology:
To evaluate the modified KMEE tool, a series of focus groups were performed to assess if each capability 
criteria (using the customised questions) were met. A scoring mechanism was designed to reflect capability 
attainment, which was visually represented in a heat map. Examples of focus groups heat maps are  presented 
for a team with low KM maturity versus a team demonstrating higher KM maturity in Tables 5.9 and 5.10 
respectively below:
Table 5.9 — Focus group demonstrating low KM Capability:  













L1 L2 L2 L2 L1 L1
L2 L3 L3 L2 L2 L1
L3  L4 L3  L2
L3   L3  L3
L3   L4  L3
L4   L5   
L4   L5   
L4      
L5      
In contrast, results from the second focus group that demonstrated a more mature KM capability is shown 
below:
Table 5.10 — Focus group demonstrating higher KM Capability:  













L1 L2 L2 L2 L1 L1
L2 L3 L3 L2 L2 L1
L3  L4 L3  L2
L3   L3  L3
L3   L4  L3
L4   L5   
L4   L5   
L4      
L5      
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Reviewing the contrasting results of the two example teams, who all belong to the same organisation, one can 
recognise the level of detail reported is invaluable for each team to understand their specific KM capabilities, 
and learn which approaches can be used to improve the KM capabilities and knowledge flow within their 
team, helping them to work more effectively and purposefully in the future.  
In this example, a business decision by the leadership of the case-study organization, all teams aim to reach a 
Level 3 in maturity as the initial maturity performance improvement target.   As such, a report was developed 
to show the gaps (if any) to reach capability of both the internal goal of Level 3 maturity, as well as what would 
be required to strive towards a Level 5 maturity, the highest level of maturity on the model.  Figure 5.1 is an 
example of how these results were visualised for leadership to aid their comprehension and ownership of the 






































































Figure 5.1  — Blue indicates the number of capabilities required to fill the gap to achieve level 3 
maturity, Green is the gap of capabilities to reach level 5 maturity.
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5.4.2 KMEE Reporting and KM Plan – A Roadmap to KM Capability Improvement 
To assist each functional area, a KM plan template was developed to suggest opportunities and methodologies 
to close the gaps, as well as to articulate business benefits to build KM capability. The full report provided to 
each team was presented and included the following:
•  The rationale for the KM Maturity Assessment
•  The date of focus group/assessment
•  Focus group participants and facilitators
•  What was working well
•  Discussion Insights
•  For each Category (People, Process, Content & IT) the following were provided
 »  A listing of gaps noted to level 3 (L3)12 
 »  Recommendation for closing the gap
•  Prioritisation map that was developed based on the perceived ease to implement the gap closure 
and the value of closing the gap.
Each team was also provided their detailed KMEE evaluation spreadsheet with assessment notes and scoring 
so that individual groups could manage their implementation plan and track progress.
The full case study described in the previous sections is published as a component of Kane’s PhD thesis and 
can be found in the TU Dublin Arrow site https://arrow.dit.ie/sciendoc/210/ .
5.5 Conclusion
The KMEE tool was developed to provide a practical link between the KM theoretical proposition and the 
practical business application that Kruger and Snyman indicated is so critical for the success of KM programs. 
This KMEE tool, with the help of a KM practitioner, translates KM terminology into local business nomenclature, 
thus enabling meaningful engagement with knowledge workers and ensuring an efficient and effective 
evaluation of the knowledge flow process within organisations, right down to front line team member level.
It could be argued that the model is very closely linked to the APQC KM-CAT™, that was by design.  However, 
feedback from the management teams involved in the case study pilots indicated a strong preference to 
maintain a link back to a “proven” benchmarking tool, hence building a positive case for the strong linkage to 
the APQC Maturity tool.  In addition, the action plans arising from the completion of the KMEE tool provided 
teams with recommendations that were in the direct control of the team to enable them to improve the 
management and sharing of their knowledge. 
12 As the business focus was to have all groups achieve a level 3 (L3) capability, focus was on closing the gaps for L3 for the fiscal year 
of the study.
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6. Chapter Six 
 Evolving Research: Presentation of a 
 Framework to Enhance Knowledge Transfer
This chapter concludes the monograph by presenting early stage research into effective Knowledge 
Management during Technology Transfer in the format of a Knowledge Transfer Enhancement Framework 
(KTE Framework).
The KTE Framework evolved over a series of brainstorming meetings and workshops, based on the experience 
of the authors (including experience with KM best practices across industries), and by applying a well-known 
Lean Six Sigma improvement methodology of Plan, Do, Check, Act (or PDCA).  The KTE Framework (Figure 6.1) 
is divided into four stages, namely: 
•  Stage 1:  KT Readiness Planning
•  Stage 2:  KT Execution
•  Stage 3:  KT Effectiveness Assessment
•  Stage 4:  KT Action Plan. 
The KTE Framework is depicted in Figure 6.1. 
Figure 6.1  — The KTE Framework (original contribution Lipa 2020)
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Further detail on the purpose and intended outcome of each of the four stages is presented in Figure 6.2. 
Figure 6.2 — Expanded KTE view of purpose and intended outcome of each of the 
four stages (original contribution Lipa 2020)
Work is on-going and it is anticipated that the development of this framework and an associated toolkit to 
enhance knowledge transfer will be published in the near future.
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